MiRNCDH- MicroRNA-516-3p, A Novel Circulating MiRNA Differentially Expressed In HCV And HCV Related HCC Egyptian Patients | 109153
Journal of Biotechnology & Biomaterials
Like us on:
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Liver disorders arising from Hepatitis C virus (HCV) infection are considered a key challenge in the field of
translational medicine. HCV and HCV related hepatocellular carcinoma (HCC) poses a heavy burden globally;
pivoting on the geographical region, Egypt showed the highest prevalence of HCV worldwide. MicroRNAs (miRNAs)
were found to regulate or be regulated by HCV infection. Recently, circulating miRNAs detected in human serum
are proposed as novel class of biomarkers for different pathological conditions. miR-516-3p is a novel miRNA that
was not widely investigated in terms of infectious diseases rather than oncology. It was recently reported as antimetastamiR
through activation of Wnt/B-catenin pathway in gastric cancer. However, among studies efforts has
been employed to investigate the alteration in the circulating miRNA pattern that is related with HCV infection and
associated HCC, miR-516-3p is scarcely discussed. Moreover, this has not been investigated in case of Egyptian HCV
patients or HCC patients. Therefore, the aim of this study is to investigate the expression profile of the novel liverassociated
miRNA, miR-516-3p, in the serum of HCV and HCC Egyptian patients. Serum samples were collected
from 50 HCV, 20 HCC Egyptian patients and 30 age-matched healthy controls. Total RNA was extracted using
Geneaid total RNA mini-kit. Reverse transcription was performed using TaqManŽ MicroRNA Reverse Transcription
Kit. Finally, miR-516 expression was quantified using qRT-PCR. Data was statistically analyzed using GraphPad
Prism 5.00 software. miR-516-3p was found to be significantly up-regulated in HCV patients compared to agematched
healthy controls (p=0.002). Also miR-516-3p showed statistically significant upregulation in HCC versus
HCV patients (p=0.0001). This study identifies miR-516-3p as a novel circulating MicroRNA. miR-516-3p was found
to be overexpressed in the serum of HCV patients. Moreover miR-516-3p showed escalated up regulation in HCC
patients. Thus shedding the light on the pivotal role of miR-516-3p in HCV and HCV induced HCC.
Samar Samir Youssef has been working in National Research Centre, Egypt since 1991. She has completed her PhD at Ain Shams University and Postdoctoral studies in France. She has published more than 25 papers in reputed journals and has been serving as a Reviewer Board Member of reputed journals.